Cargando…

Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy

Detalles Bibliográficos
Autores principales:	Mohyuddin, Ghulam Rehman, Chakraborty, Rajshekhar, Calip, Gregory S., Ascha, Mustafa S., Wang, Xiaoliang, Rubinstein, Samuel M., Tuchman, Sascha, Costa, Luciano, Haaland, Benjamin, Giri, Smith, Mian, Hira, Fonseca, Rafael, Sborov, Douglas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758218/ https://www.ncbi.nlm.nih.gov/pubmed/36526617 http://dx.doi.org/10.1038/s41408-022-00769-4

Ejemplares similares

Is aggressive treatment of smoldering myeloma the path to curing myeloma?
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2023)

Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma
por: Basali, Diana, et al.
Publicado: (2020)

Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
por: Fatoki, Raleigh Ayoolu, et al.
Publicado: (2022)

Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma
por: Najjar, Mimi, et al.
Publicado: (2023)

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
por: McCurdy, Arleigh, et al.
Publicado: (2023)

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
por: Tariq, Syed Maaz, et al.
Publicado: (2023)

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation
por: Diamantidis, Michael D., et al.
Publicado: (2022)

Hospitalization at the end of life in patients with multiple myeloma
por: Abbasi, Saqib, et al.
Publicado: (2021)

Venetoclax for the treatment of translocation (11;14) AL amyloidosis
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

Near tetrapoloid karyotype with translocation t(11;14) in a Moroccan patient with amyloid light-chain amyloidosis and multiple myeloma
por: Hamdaoui, Hasna, et al.
Publicado: (2020)

Multiple myeloma with t(11;14): impact of novel agents on outcome
por: Puertas, Borja, et al.
Publicado: (2023)

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
por: Kaufman, Jonathan L., et al.
Publicado: (2021)

Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence
por: Kitadate, Akihiro, et al.
Publicado: (2021)

Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study
por: Ni, Ivyna Bong Pau, et al.
Publicado: (2012)

Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020
por: Van Oekelen, Oliver, et al.
Publicado: (2022)

Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma
por: Gil, Kellen, et al.
Publicado: (2022)

Financial toxicity in hematological malignancies: a systematic review
por: Ouchveridze, Evguenia, et al.
Publicado: (2022)

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
por: Pan, Darren, et al.
Publicado: (2021)

The chromosome translocation (11;14)(p13;q11) associated with T cell acute leukemia. Asymmetric diversification of the translocational junctions
Publicado: (1990)

Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma
por: Wang, Jinghua, et al.
Publicado: (2022)

Palbociclib regulates the expression of dihydrofolate reductase and the cell cycle to inhibit t (11;14) multiple myeloma
por: Wang, Yazhu, et al.
Publicado: (2022)

Is t(11;14)(q13;q32) good or bad for newly diagnosed multiple myeloma?
por: Liu, Yang, et al.
Publicado: (2023)

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
por: Bahlis, Nizar J., et al.
Publicado: (2021)

The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl‐2 inhibitor (ABT‐199) displays synergistic anti‐myeloma effects in myeloma cells without a t(11;14) translocation
por: Sundaramoorthy, Pasupathi, et al.
Publicado: (2018)

Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2021)

What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?
por: Gao, Wen, et al.
Publicado: (2020)

CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
por: Jian, Yuan, et al.
Publicado: (2022)

Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
por: Abdallah, Al‐Ola, et al.
Publicado: (2021)

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
por: Szita, Virág Réka, et al.
Publicado: (2022)

Induction of t(11;14) IgH enhancer/promoter-cyclin D1 gene translocation using CRISPR/Cas9
por: Tsuyama, Naohiro, et al.
Publicado: (2019)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Non-secretory multiple myeloma: from biology to clinical management
por: Dupuis, Megan Murray, et al.
Publicado: (2016)

Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma
por: Usmani, Saad Z., et al.
Publicado: (2021)

Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer
por: Whitaker, Kristen D., et al.
Publicado: (2022)

Primary Myelofibrosis Presenting as Extramedullary Hematopoiesis in a Transplanted Liver Graft: Case Report and Review of the Literature
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2016)

A Rare Presentation of a Rare Disease: Pulmonary Lymphomatoid Granulomatosis
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2012)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature
por: Abuelgasim, Khadega A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9rjnooo08jc1r2a214bofukcdf